A Single-arm Phase II Study of Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Who Failed a Platinum-based Chemotherapy
Latest Information Update: 06 Jan 2025
Price :
$35 *
At a glance
- Drugs Atezolizumab (Primary) ; Cabozantinib (Primary)
- Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 01 Jan 2025 Status changed from recruiting to completed.
- 22 Jan 2022 Trial design presented at the 2022 Gastrointestinal Cancers Symposium
- 23 Aug 2021 New trial record